Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference




Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference being held from February 8-9, 2023.

Details of the event are as follows:

Date: Thursday, February 9, 2023

Time: 2:10 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com